Conference Report

Coverage of the 7th International Workshop on Adverse Drug Reactions And Lipodystrophy in HIV

Source: CCO Independent Conference Coverage of the 2005 International Workshop on Adverse Drug Reactions And Lipodystrophy in HIV*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Coverage of the 7th International Workshop on Adverse Drug Reactions And Lipodystrophy in HIV


CME Program Director: John P. Phair, MD

Faculty:

  • Judith S. Currier, MD, MSc
  • Peter Reiss, MD, PhD

CME CREDIT INFORMATION

Release Date: 01/27/06

Expiration Date: 01/26/07


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review recent data regarding the metabolic side effects associated with specific antiretroviral agents
  • Describe data on potential therapeutic interventions for metabolic complications and lipodystrophy in HIV-infected patients
  • Discuss antiretroviral treatment strategies for preventing and managing metabolic complications and lipodystrophy in HIV-infected patients

Topics covered include:

  • Overview
  • Effects of Stavudine Switch on Peripheral Lipoatrophy, Lipids, and Lipid-Associated Factors
  • Effects of Switching Stavudine to Tenofovir or Abacavir on Facial Lipoatrophy
  • Predictors of Lipoatrophy
  • Effects of Uridine Supplementation on Lipoatrophy in HIV-Infected Patients
  • Effects of Pravastatin on Dyslipidemia and Peripheral Lipoatrophy in HIV-Infected Patients
  • Efficacy and Safety of Extended-Release Niacin in HIV-Infected Patients With Dyslipidemia
  • Effects of Protease Inhibitors on Insulin Resistance in Healthy Volunteers
  • Relationship Between Hepatic Steatosis and Insulin Resistance in HIV-Infected Patients
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.